CA2728623A1 - Combination treatment of glaucoma - Google Patents

Combination treatment of glaucoma Download PDF

Info

Publication number
CA2728623A1
CA2728623A1 CA2728623A CA2728623A CA2728623A1 CA 2728623 A1 CA2728623 A1 CA 2728623A1 CA 2728623 A CA2728623 A CA 2728623A CA 2728623 A CA2728623 A CA 2728623A CA 2728623 A1 CA2728623 A1 CA 2728623A1
Authority
CA
Canada
Prior art keywords
punctum
latanoprost
delivery system
days
eye drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2728623A
Other languages
English (en)
French (fr)
Inventor
Zuhal Butuner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelion Therapeutics Inc
Original Assignee
QLT Plug Delivery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QLT Plug Delivery Inc filed Critical QLT Plug Delivery Inc
Publication of CA2728623A1 publication Critical patent/CA2728623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
CA2728623A 2008-06-24 2009-06-24 Combination treatment of glaucoma Abandoned CA2728623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7528408P 2008-06-24 2008-06-24
US61/075,284 2008-06-24
PCT/US2009/048452 WO2010008883A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Publications (1)

Publication Number Publication Date
CA2728623A1 true CA2728623A1 (en) 2010-01-21

Family

ID=41431875

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2728623A Abandoned CA2728623A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Country Status (7)

Country Link
US (1) US20090318549A1 (https=)
EP (1) EP2303184A4 (https=)
JP (1) JP2011525388A (https=)
CN (1) CN102105118A (https=)
CA (1) CA2728623A1 (https=)
TW (1) TW201012469A (https=)
WO (1) WO2010008883A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1765454T3 (en) 2004-07-02 2016-05-02 Mati Therapeutics Inc Device for submission of treatment medium to eye
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
NZ583858A (en) 2007-09-07 2012-08-31 Quadra Logic Tech Inc Lacrimal implant detection with detection device
CN102123713A (zh) * 2008-05-09 2011-07-13 Qlt栓塞输送公司 治疗青光眼和眼高血压的活性剂的持续释放递送
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US8591484B2 (en) 2010-09-15 2013-11-26 AlphaMed, Inc. Lacrimal punctum measurement and occlusion
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP2755615B1 (en) 2011-09-14 2022-04-06 Forsight Vision5, Inc. Ocular insert apparatus
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
US20140206708A1 (en) * 2013-01-24 2014-07-24 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9424722B2 (en) * 2014-05-14 2016-08-23 Unlimited Liability, LLC Smart memory material lock devices
JP6555758B2 (ja) * 2014-09-22 2019-08-07 株式会社カネカ 内視鏡用注射器具
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11291847B2 (en) * 2015-06-16 2022-04-05 The Regents Of The University Of Colorado, A Body Corporate Systems and methods for preventing, diagnosing, and/or treating one or more medical conditions via neuromodulation
CN105879126A (zh) * 2016-03-24 2016-08-24 杭州亚慧生物科技有限公司 一种超润滑血清白蛋白泪点塞及其制备方法
EP3773330B1 (en) * 2018-03-29 2025-03-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
CN109568138B (zh) * 2019-01-10 2021-06-25 新疆国际旅行卫生保健中心 药片分割装置
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US5589563A (en) * 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
CA2134087C (en) * 1992-04-24 2007-07-17 Robert S. Ward Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
CA2513751C (en) * 2003-01-24 2012-01-10 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
EP1603485A4 (en) * 2003-02-26 2011-03-30 Medivas Llc BIOACTIVE STENTS AND METHOD OF USE THEREOF
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2007047744A2 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
EP2004172B1 (en) * 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
CN102670352A (zh) * 2007-09-07 2012-09-19 Qlt股份有限公司 用于泪腺植入物的插入和抽出工具
CA2698508C (en) * 2007-09-07 2017-06-06 Alan R. Rapacki Lacrimal implants and related methods
SG188155A1 (en) * 2008-02-18 2013-03-28 Quadra Logic Tech Inc Lacrimal implants and related methods
WO2009134371A2 (en) * 2008-04-30 2009-11-05 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
CN102123713A (zh) * 2008-05-09 2011-07-13 Qlt栓塞输送公司 治疗青光眼和眼高血压的活性剂的持续释放递送

Also Published As

Publication number Publication date
EP2303184A1 (en) 2011-04-06
US20090318549A1 (en) 2009-12-24
EP2303184A4 (en) 2013-06-19
JP2011525388A (ja) 2011-09-22
CN102105118A (zh) 2011-06-22
WO2010008883A1 (en) 2010-01-21
TW201012469A (en) 2010-04-01

Similar Documents

Publication Publication Date Title
US20090318549A1 (en) Combination treatment of glaucoma
CA2722971C (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US10632012B2 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EP2389221B1 (en) Sustained released delivery of one or more agents
US20100274224A1 (en) Lacrimal implant body including comforting agent
US20140025022A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CA2872338C (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
HK1156835A (zh) 青光眼的聯合治療
HK1158951A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
HK1162151B (en) Sustained released delivery of one or more agents

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140625